Kang Yu-Chan, Chen Ming-Hong, Lin Chung-Ying, Lin Chih-Yun, Chen Yen-Ta
Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung.
Institute of Allied Health Sciences, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan.
Ther Adv Drug Saf. 2021 Mar 21;12:2042098621997727. doi: 10.1177/2042098621997727. eCollection 2021.
The risk of primary aristolochic acid (AA)-associated urothelial carcinoma (AA-UC) has been summarized by a 2013-published meta-analysis. Given that additional evidence has been continuously reported by original studies, an updated meta-analysis is needed. Meanwhile, to complete the whole picture, a systematic review of molecular alterations observed in AA-urinary tract cancers (AA-UTC) was also performed.
We searched PubMed, Embase and four Chinese databases up to October 2020. Observational studies comparing risk or oncologic outcomes of UTC between patients with and without AA exposure were eligible for systematic review and meta-analysis. Studies investigating molecular alterations in AA-UTC using human tissue samples were eligible for systematic review.
In total, 38 and 20 studies were included in the systematic review and meta-analysis, respectively. Exposure to AA led to an overall increased risks of primary UTC [UC and renal cell carcinoma (RCC)] (OR 6.085, 95% CI 3.045-12.160) and postoperatively recurrent UC (RR 1.831, 95% CI 1.528-2.194). Subgroup analysis of postoperative primary AA-upper tract UC (AA-UTUC) showed increased risks of bladder recurrence (adjusted RR 1.949, 95% CI 1.462-2.597) and contralateral UTUC recurrence (crude RR 3.760, 95% CI 2.225-6.353), worse overall survival (adjusted HR 2.025, 95% CI 1.432-2.865) and worse disease-specific survival (adjusted HR 3.061, 95% CI 1.190-7.872), but no effect on cancer-specific survival (adjusted HR 0.772, 95% CI 0.269-2.215). High mutation load with AA mutational signature presenting largely in the putative driver genes was observed in AA-UTUC. In contrast, AA mutational signature is rarely found in the mutated RCC driver genes and the mutation load in AA-RCC is low. Therefore, AA has different roles in the genesis of UTUC and RCC.
Implementing effective strategies to completely protect people from exposure to AA is urgently needed. Additionally, more effort should be made in identifying the precise carcinogenic mechanisms of AA to determine the future treatment strategies.
The association between aristolochic acid (AA) and primary urothelial carcinoma (UC) has been summarized by a 2013-published meta-analysis. Given that additional evidence has been reported in the past 7 years, an updated meta-analysis is needed. Meanwhile, to complete the whole picture, a systematic review of molecular changes possibly involved in AA-mediated urinary tract carcinogenesis was also performed. We searched PubMed, Embase and four Chinese databases for human studies up to October 2020. Studies comparing the risk of urinary tract cancer (UTC) between patients with and without AA exposure and studies investigating the molecular changes in AA-associated UTC (AA-UTC) using human tissue samples were eligible for inclusion. Thirty-eight studies were finally included. The results showed that exposure to AA was associated with a 6-fold increased risk of primary UTC (UC and renal cell carcinoma, RCC) and a 1.8-fold increased risk of postoperatively recurrent UC. After studies reporting primary AA-upper tract UC (AA-UTUC) were analyzed, a 1.9-fold increased risk of bladder recurrence and a 3.8-fold increased risk of contralateral UTUC recurrence was observed. Additionally, exposure to AA worsened the postoperative survival of patients with UTUC by a 2-fold increased risk of overall death and a 3-fold increased risk of death from other diseases and recurrences. However, there was no effect on death due to cancer. Lastly, AA seemed to play different roles in the etiology of UTUC and RCC based on the observations of different mutation loads and different distributions of AA-induced mutations in AA-UTUC and AA-RCC samples. Implementing effective strategies to completely protect people from exposure to AA is urgently needed. Moreover, more effort should be made in identifying the precise carcinogenic mechanisms of AA-UTC to determine the future treatment strategies.
2013年发表的一项荟萃分析总结了原发性马兜铃酸(AA)相关尿路上皮癌(AA-UC)的风险。鉴于原始研究不断报告新的证据,需要进行更新的荟萃分析。同时,为全面了解情况,还对AA相关尿路癌(AA-UTC)中观察到的分子改变进行了系统综述。
我们检索了截至2020年10月的PubMed、Embase和四个中文数据库。比较有和没有AA暴露的患者尿路癌(UTC)风险或肿瘤学结局的观察性研究符合系统综述和荟萃分析的条件。使用人体组织样本研究AA-UTC分子改变的研究符合系统综述的条件。
系统综述和荟萃分析分别纳入了38项和20项研究。暴露于AA导致原发性UTC[UC和肾细胞癌(RCC)]的总体风险增加(OR 6.085,95%CI 3.045-12.160)以及术后复发性UC的风险增加(RR 1.831,95%CI 1.528-2.194)。术后原发性AA上尿路UC(AA-UTUC)的亚组分析显示膀胱复发风险增加(调整后RR 1.949,95%CI 1.462-2.597)和对侧UTUC复发风险增加(粗RR 3.760,95%CI 2.225-6.353),总生存期更差(调整后HR 2.025,95%CI 1.432-2.865)以及疾病特异性生存期更差(调整后HR 3.061,95%CI 1.190-7.872),但对癌症特异性生存期无影响(调整后HR 0.772,95%CI 0.269-2.215)。在AA-UTUC中观察到高突变负荷,且AA突变特征主要出现在假定的驱动基因中。相比之下,在突变的RCC驱动基因中很少发现AA突变特征,且AA-RCC中的突变负荷较低。因此,AA在UTUC和RCC的发生中具有不同作用。
迫切需要实施有效的策略,以全面保护人们免受AA暴露。此外,应更加努力确定AA的确切致癌机制,以确定未来的治疗策略。
2013年发表的一项荟萃分析总结了马兜铃酸(AA)与原发性尿路上皮癌(UC)之间的关联。鉴于在过去7年中报告了更多证据,需要进行更新的荟萃分析。同时,为全面了解情况,还对可能参与AA介导的尿路致癌作用的分子变化进行了系统综述。我们检索了PubMed、Embase和四个中文数据库,以查找截至2020年10月的人体研究。比较有和没有AA暴露的患者尿路癌(UTC)风险的研究以及使用人体组织样本研究AA相关UTC(AA-UTC)分子变化的研究符合纳入条件。最终纳入了38项研究。结果表明,暴露于AA与原发性UTC(UC和肾细胞癌,RCC)风险增加6倍以及术后复发性UC风险增加1.8倍相关。在分析报告原发性AA上尿路UC(AA-UTUC)的研究后,观察到膀胱复发风险增加1.9倍,对侧UTUC复发风险增加3.8倍。此外,暴露于AA使UTUC患者术后生存率恶化,总体死亡风险增加2倍,因其他疾病和复发导致的死亡风险增加3倍。然而,对癌症死亡没有影响。最后,基于对AA-UTUC和AA-RCC样本中不同突变负荷和AA诱导突变的不同分布的观察,AA似乎在UTUC和RCC的病因中发挥不同作用。迫切需要实施有效的策略,以全面保护人们免受AA暴露。此外,应更加努力确定AA-UTC的确切致癌机制,以确定未来的治疗策略。